BBNX Beta Bionics, Inc.
USHealthcareAs of 2026-07-09 16:00
Why BBNX matters now
Beta Bionics, Inc. (BBNX) is a US stock in Healthcare. The latest InvestLog snapshot shows $16.43 with +1.55% on the session and $732.1M in market capitalization; recent performance reads 1-month +47.35% and YTD -54.45%.
The latest financial table shown here is Q1 2026, with revenue of $27.6M, net income of $-21.9M, and EPS of $-0.49. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -9.9%.
The latest indexable market news headline is "Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $20.00; recent insider activity includes Jones Christy filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.27
P/S
5.61
EV/EBITDA
-9.37
DCF Value
$-155.73
FCF Yield
-9.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
57.2%
Operating Margin
-70.1%
Net Margin
-60.3%
ROE
-23.0%
ROA
-21.8%
ROIC
-27.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $27.6M | $-21.9M | $-0.49 |
| Q4 2025 | $32.1M | $-13.5M | $-0.30 |
| FY 2025 | $100.3M | $-73.2M | $-1.81 |
| Q3 2025 | $27.3M | $-14.2M | $-0.33 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$19.86
Target (Median)
$20.00
Target Range
$14.00 - $25.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Equipment & Services
Country
US
Exchange
—
Beta
3.39
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.